Hidradenitis suppurativa treated with follicular unit excision: A prospective controlled 24-week pilot study

Not Applicable

• Conditions: Hidradenitis suppurativa; Skin - Dermatological conditions

• Registration Number: ACTRN12624000388516
• Lead Sponsor: Dr Bevin Bhoyrul

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2024-04-03
• Last Update Posted: 8 April 2024

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

1.Male and female patients with HS aged 18 years and above
2.Mild-moderate HS defined by Hurley stage 1 up to 2A
3.Minimum diagnosis of 3 months prior to baseline
4.Active HS present for at least 3 months from initial diagnosis.

Exclusion Criteria

1.Current treatment with antibiotics, retinoids, immunosuppressants or biologic agents at the discretion of the investigator/research team.
2.Extensive scarring.
3.Absence of terminal hairs in target areas.
4.Previous laser hair removal in target areas.
5.Pregnant or lactating women

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in HS severity score based on validated assessment tools.<br>This will be assessed as a composite outcome.[1. Hidradenitis suppurativa clinical response score (HiSCR)<br>2. Hidradenitis suppurativa – Physician’s global assessment (HS-PGA)<br>3. International Hidradentitis Suppurativa Severity Score System (IHS4)<br><br> Baseline and at week 6, 12 and 24 after follicular unit extraction.];Change in pain score[Pain score (NRS30) Baseline and at week 6, 12 and 24 after follicular unit extraction.];Number of abscesses and nodule counts at each visit.<br>This will be assessed as a composite outcome.[Physical assessment conducted by a medical professional Baseline and at week 6, 12 and 24 after follicular unit extraction.]

Secondary Outcome Measures

Name	Time	Method
umber and location of disease flares before and after follicular unit extraction.<br>This will be assessed as a composite outcome.<br>[Physical examination at baseline visits and during follow ups. Participants will also be given a sheet to document number and location of flares. At baseline, week 6, 12 and 24 after follicular unit extraction.]